Since its establishment, Bio-Thera Solutions has consistently regarded R&D innovation as its core development strategy, continuously investing in technological breakthroughs and platform development in the vaccine field. The company has successively been approved by the Jilin Provincial Department of Science and Technology to establish the “Jilin Provincial Vaccine Technology Innovation Center,” by the Jilin Provincial Development and Reform Commission to establish the “Jilin Provincial Vaccine Engineering Research Center,” by the Changchun National Biotechnology Industry Base to be designated as the “Changchun National Biotechnology Industry Base Vaccine Engineering Research Center,” by the Jilin Provincial Department of Industry and Information Technology to be recognized as a “Provincial Enterprise Technology Center,” and by the National Development and Reform Commission to be recognized as a “National-Level Enterprise Technology Center.”
The company has consistently prioritized R&D innovation and continuously optimized resource allocation. It boasts comprehensive research and development capabilities as well as pilot-scale production facilities, with laboratory and pilot-scale workshop space totaling approximately 11,000 square meters. The core infrastructure includes a Biosafety Level 2 laboratory, GMP-compliant pilot-scale manufacturing units supporting multiple technological platforms, and specialized analytical laboratories, enabling end-to-end R&D spanning molecular design and screening, basic research, and pilot-scale scale-up. The facility is equipped with more than 1,300 pieces of state-of-the-art instrumentation and equipment, including fully automated inoculation-and-harvest integrated systems, continuous-flow centrifuges, large-scale bioreactors, chromatography purification systems, mRNA vaccine production equipment, nanoparticle size analyzers, fluorescence quantitative PCR instruments, ELISPOT readers, flow cytometers, ultra-high-performance liquid chromatographs, and fully automated nucleic acid–protein analysis systems. These advanced production and testing assets simultaneously support the R&D, pilot-scale manufacturing, and quality control needs for a diverse portfolio of products, including viral vaccines, bacterial vaccines, recombinant protein vaccines, and adjuvants.
